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Abstract
Background: The pre-symptomatic stage of Rheumatoid arthritis (RA) is associated with pro-inflammatory cytokines and
autoantibodies. High levels and epitope spread by Rheumatoid factors (RhF) and autoantibodies to citrullinated proteins
signify progression towards disease expression. In established RA, the persistence of high autoantibody levels reflects
production by both long-lived plasma cells and short-lived plasmablasts. Neither the relative contributions to pathogenesis
by autoantibodies from either source, nor the factors responsible for deciding the fate of autoantigen specific ‘parent’ B-
cells, is understood. Phenotypic markers identifying subsets of autoreactive B-cells are therefore of interest in understanding
the origin and perpetuation of the autoimmune response in RA. One such phenotypic marker is the rat monoclonal
antibody, 9G4, which recognises an idiotope on immunoglobuins derived from the inherently autoreactive VH-gene, VH4-
34. We therefore investigated whether the 9G4 idiotope was expressed on autoantibodies in patients with RA.
Methodology/Principal Findings: Sera from 19 patients with established RA and those with ,1year history of untreated
polyarthritis either resolving into RA (n = 42) or non-RA diagnosis (n = 31) were included. Autoantibodies to cyclic
citrullinated peptides (CCP), RhF and co-expression of the 9G4 idiotope were measured by ELISA. 9G4 recognised a
population of anti-CCP antibodies in the majority of sera from patients with established disease and also in samples from
patients with early disaese. 9G4+RhF levels were generally lower and not associated with positivity for, or levels of 9G4+CCP.
Conclusions/Significance: The persistence of 9G4+ immunoglobulins, of any isotype, in serum is rare. We describe here the
novel finding of 9G4 expression on anti-CCP antibodies in patients from the earliest symptoms of RA through to established
disease. Our results suggest that 9G4 expression on anti-CCP autoantibodies was not due to polyclonal expansion of VH4-
34-encoded immunoglobulins. These studies may therefore provide a new focus for investigation into the evolution of the
autoimmune response in RA patients.
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Introduction
The serology of patients with Rheumatoid arthritis (RA) is
characterised by persistently raised levels of autoantibodies of two
main specificities, being those against Fc of IgG (Rheumatoid
factors, RhF) and to peptide sequences on a number of different
proteins which have undergone citrullination (anti-citrullinated
protein/peptide antibodies - ACPA) [1–3]. Multiple isotypes of
both RhF and ACPA and epitope spread of ACPA can precede
the development of clinical disease by many months or years [4–
8]. Detection of ACPA in the clinical setting however is usually
through binding to commercially prepared combinations of cyclic
citrullinated peptides (CCP), which detect antibodies of most but
not all specificities [9]. The RhF response can also be both
exaggerated and show evidence of somatic hypermutation [10,11].
Although unaffected relatives and relatives with undifferentiated
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arthritis can also have ACPA and RhF, albeit at much lower titres,
the number of isotypes is more limited and sera from patients with
undifferentiated arthritis also recognise fewer citrullinated epitopes
[12].
The usage of some genes encoding particular variable heavy
chains of immunoglobulins (IGVH) has been associated with the
development of autoantibodies [11,13,14], with those encoded by
VH4-34 being the prototype [15]. Identification of B-cells and
antibodies using this VH gene is possible using the rat monoclonal
antibody, 9G4, which recognises a unique comformational epitope
largely confined within framework 1 of VH4-34-derived immu-
noglobulins (Igs) [16]. This epitope is inherently autoreactive as it
recognises N-acetyllactosamine (NAL) on a number of microbial
glycolipids, self glycoproteins and on cells undergoing apoptosis
[17–19]. 9G4+ B-cells can constitute up to 10% of peripheral B-
cells although VH4-34-derived serum Igs constitute less than 1%
of total Igs [20]. The level of VH4-34-derived Igs can however
transiently increase in response to infections [19,21–23]. The
ability to recognise a number of self-antigens via the NAL-epitope
may thus be advantageous in clearing damaged, apoptotic or
neoplastic cells, but may also increase the risk of autoimmunity,
particularly if the conventional binding site on the same molecule
undergoes mutation to an autoreactive specificity. VH4-34 gene
usage has been shown to be obligatory for the production of most
pathogenic IgM cold-agglutinins and has been for demonstrated in
IgM-RhF, IgG anti-dsDNA antibodies in systemic lupus erythe-
matosus (SLE), and IgM anti-myeloperoxidase antibodies in
systemic vasculitis [24–27]. The consequence of allowing the
inherently autoreactive VH4-34-derived B cell populations to
persist within the B-cell repertoire, across all ethic groups, implies
that differentiation to antibody secretion, except in the context of
infection, must be under strict physiological control. Censoring of
9G4+ B-cells may be due to anergy associated with high-dose
antigen exposure, as the apparent block to maturation into Ig
secretion can be overcome by culturing isolated 9G4+ cells in vitro
with cytokines and CD70 stimulation [22].
Preliminary studies in our laboratory showed that sera from
some patients with established RA contained 9G4+ antibodies to
CCP [28]. In the present cross-sectional study, we have extended
analysis of 9G4 expression to include sera from patients with the
earliest symptoms of RA (,6 weeks polyarthritis) and disease
controls, and in patients with established disease, using samples
from a well-described cohort [29]. We have also measured serum
autoantibody levels and class and included anti-microbial
antibodies in the analysis.
Patients and Methods
Patients
Patients were attending the Rheumatology Department in the
Hospital de Santa Maria, Lisbon Academic Medical Centre and
Hospital da Luz, Lisbon, Portugal. Serum samples were collected
from 40 consecutive patients with untreated polyarthritis of less
than 6 weeks duration of symptoms and from 33 untreated early
polyarthritis patients with .6 weeks and ,1 year of disease
history. Serum samples were also collected from 19 patients with
established seropositive RA from Lisbon Academic Medical
Centre (Est-RA) Samples from Lisbon centers were stored at
Biobanco-IMM, Lisbon Academic Medical Centre. All patients
with established disease had received a variety of therapies but
patients currently or previously treated with rituximab were
excluded. Serum samples from 21 healthy controls (HC) were also
collected. The local ethics committees (Comissa˜o de E´tica do
Hospital de Santa Maria, Lisbon, Portugal and University College
London Ethics Committee, London, United Kingdom) approved
the study and all patients signed an informed consent prior to any
protocol-specific procedure.
Measurement of IgM and IgA Rheumatoid factor (RhF)
RhF were detected using affinity purified rabbit IgG (Sigma
Aldrich, St Louis, USA) as substrate. Binding of sera (diluted 1/
200) on coated and uncoated wells was measured using goat-anti-
human IgA- or IgM-horeradish peroxidase (HRP) conjugate (The
Binding Site, Birmingham, UK). In all ELISAs, color development
was with tetramethylbenzidine (TMB-Sigma-Aldrich, Gillingham,
UK). After subtracting background binding (to uncoated wells),
arbitrary units (AU) of binding were calculated by reference to
control sera and a standard curve constructed from high positive
control sera for each isotype. Cuts-off were 10 AU/ml and 23
AU/ml for IgM and IgA-RhF respectively. IgG-RhF was detected
following pepsin digestion of sera with detection of IgG-Fab2
fragments using HRP-conjugated goat anti-IgG-Fab2, as previ-
ously described [30]. Reagents were supplied by TheraTest
(Chicago, USA).
Anti-cyclic citrullinated peptide antibodies
Antibodies to citrullinated peptides were measured using
commercial ELISA plates coated with second generation citrulli-
nated peptides (CCP2) (FCCP600; Axis Sheild Diagnostics,
Dundee, UK). Sera was added to plates at a dilution of 1/200.
HRP-conjugated sheep anti-human IgG, 2IgM or –IgA (The
Binding Site, UK) were used to detect classes of anti-CCP2, and
the assay was developed as above for RhF. Levels of IgG-CCP2
were calculated as per manufacturers instructions and IgM- and
IgA-CCP2 calculated following in-house protocol. Cut-off values
were defined according to the manufacturer’s instructions for IgG-
CCP2 (5 U/ml) or defined as mean 6 3SD from healthy controls
for IgM-CCP2 and IgA-CCP2 (26 AU/mL and 10 AU/mL,
respectively).
Expression of 9G4 on RhF and on antibodies to CCP2
For detection of 9G4 expression on either RhF or CCP2, sera
(diluted 1/50 in RD6Q diluent, R & D Systems, Abingdon, UK)
were added to respective antigen coated wells of ELISA plates.
Following initial incubation, the 9G4 reagent (IGM Bioscience,
Palo Alto, USA) was added at a concentration of 2 mg/ml to one
side of the plate, the duplicate serum-incubated wells receiving
diluent buffer instead of 9G4. 9G4 binding to RhF was detected
using biotinylated goat anti-rat IgG (Abcam, Cambridge, UK),
and a streptavidin–HRP visualization system. An affinity purified
HRP-conjugated sheep anti-rat-IgG reagent (Amersham, UK) was
used to detect 9G4 recognition of CCP2-binding antibodies.
Results were calculated and presented as optical densities (OD at
450 nm) following the subtraction of any background binding in
the absence of the 9G4 reagent. Results exceeding mean 6 3 SD
of 5 HC sera were regarded as positive.
Separation of sera using Protein G columns
Sera from 4 patients with established RA which had both IgM-
and IgG-class autoantibodies to CCP2, which also bound the 9G4
reagent, were separated on Protein G columns using conventional
techniques [31]. Eluted fractions (using low-pH) and flow-through
fractions were then tested for IgM-, IgG- and 9G4-CCP2 activity,
as described above.
9G4 Expression on Autoantibodies in RA Patients
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Statistical analysis
Statistical differences were determined using GraphPad Prism
(GraphPad, San Diego, USA). For populations not following a
normal distribution, non-parametric statistics were used (Mann-
Whitney U test) to compare independent groups. Linear regression
(Spearman’s rank correlation) was used to determine relationships
between variables. Differences were considered statistically signif-
icant for p,0.05.
Results
Characteristics of patient cohorts
Clinical details of patients with established RA, untreated
polyarthritis, together with HC, are shown in Table 1. In patients
with a history of polyathritis of ,6 weeks (n = 40), after a
minimum follow-up of 3 months, 14/40 patients fulfilled the 2010
American College of Rheumatology (ACR)/European League
Against Rheumatism (EULAR) criteria for RA [32] and were
classified as Very Early Rheumatoid Arthritis (VERA) patients.
The remaining early polyarthritis patients (n = 26), who did not
evolve into RA, were classified as Very Early Non-RA (VENRA).
Patients in the VENRA group were resolved into diagnostic
categories of spondyloarthritis (6), SLE (5), polymyalgia rheuma-
tica (4), microcrystalline arthritis (2), Sjo¨gren syndrome (1),
undifferentiated diffuse connective tissue disease (1), viral polyar-
thritis (1), arthritis associated with malignancy (1) and 5 patients
entered spontaneously into remission (self-limiting polyarthritis). In
the second group of untreated polyarthritis patients (n = 33), who
had more than 6 weeks history but less than one year of disease
duration, those who after a minimum follow-up of 2 years fulfilled
the 2010 ACR/EULAR criteria for RA (n = 28) were classified as
Early RA (ERA) [32]. The remaining 5 untreated early
polyarthritis patients who did not evolve into RA were classified
as Early Non-RA (ENRA) (all with undifferentiated arthritis).
Comparing VERA with VENRA and ERA with ENRA, there
were no significant differences with respect to age, number of
tender joints, ESR or DAS28, although patients in the ERA
cohort had significantly more swollen joints than ENRA (Table 1).
9G4+autoantibodies in early and established RA
Although the numbers of patients in each early RA cohort were
low, relative levels of 9G4 binding to each autoantigen specificity
in patients and HC showed that overall, 9G4 binding to the
citrullinated substrate appeared greater than that by RhF
(Figure 1A and B). 9G4 expression on autoantibodies in VERA
patients was largely restricted to those targeting citrullinated
peptides (6/14 compared with 1/14 for RhF). 9G4 expression was
borderline positive on CCP2-binding antibodies in 2 samples in
the VENRA control group. In the ERA cohort, 9G4 expression
was similar for both autoantibody specificities but in Est-RA,
virtually all sera contained 9G4+CCP2 activity (18/19) compared
with 6/19 positive for 9G4+RhF. In Figure 2A and B, IgG-CCP2
and IgM-RhF were the main specificities present in patients with
the earliest disease (VERA cohort). IgM class autoantibodies of
both specificities, but not IgA- or IgG- autoantibodies, were also
present in a proportion of VENRA patients (4/26 with IgM-CCP2
and 2/26 with IgM-RhF), but not in patients in the ENRA cohort
(0/5). 9G4+ expression was borderline positive on CCP2-binding
antibodies in 2 samples in the VENRA control group, both of
which contained IgM-CCP2 only (Figure 2A). The percentage of
samples positive for 9G4+CCP2 in the ERA cohort was the same
as that for 9G4+RhF (39%). The percentage of samples positive
for 9G4 binding in the established RA cohort however was nearly
100% whereas the percentage containing 9G4+RhF remained
around 30%. Levels of binding also appeared considerably lower
for 9G4+RhF than for 9G4+CCP2 (Figure 2B; Figure 1).
Comparison of isotypes and 9G4 expression in individual
patients
Figures 3–5 show autoantibody isotypes (anti-CCP2 and RhF)
and corresponding 9G4 expression in sera from individual patients
in the VERA, ERA and Est-RA cohorts respectively. Serum
autoantibody results were ranked on the basis of the relative levels
of IgG-CCP2 antibodies in order to compare positivity for
individual specificities in each patient. In the VERA cohort
(Figure 3), 9G4 expression on CCP2-binding antibodies was
evident in all samples which also had significant IgG-CCP2,
although 2 had very low/borderline expression. IgM- and IgA-
CCP2 were present in only 2 of these samples. IgM-RhF was
present in 8 samples, 2 of which were also positive for IgA-RhF,
Table 1. Demographic data of healthy controls, patients with untreated polyarthritis and patients with established RA.
Clinical features Healthy Controls VERA VENRA ERA ENRA Est-RA
Median and range
unless otherwise indicated (n = 21) (n =14) (n =26) (n=28) (n=5) (n=19)
Age (years) 52 (22–66) 50 (26–94) 41 (24–83) 48 (17–79) 45 (41–66) 54 (21–77)
Sex (% female) 67 93 73 82 80 68
Disease duration NA ,6 ,6 8 (2–12) 3 (3–11) 5 (1–20)
(time) weeks weeks months months years
Swollen joints NA 16 (0–28) 2 (0–22) 6 (0–26)* 1 (0–7)* 3 (1–22)
Tender joints NA 12 (1–28) 7 (0–25) 6 (0–26) 3 (1u7–7) 4 (1–22)
ESR (mm/1st hour) ND 39 (3–95) 27 (4–120) 21 (2–120) 9 (6–33) 25 (5–95)
DAS28 (mean 6 SD) NA 6.161.7 4.961.9 5.161.4 3.861.3 4.761.4
NAa: not applicable, NDb: not determined, *p,0.05 (Mann Whiney Rank sum).
Results for healthy controls (HC) and patients with untreated polyarthritis of either#6 weeks duration (Very Early-VE) and subsequently diagnosed as RA (VERA) or Non-
RA (VENRA) and patients with .6 weeks and #1 year history of polyarthritis (Early-E) subsquently diagnosed with RA (ERA) or a different clinical diagnosis Non-RA
(ENRA). Est-RA: Established RA.
doi:10.1371/journal.pone.0107513.t001
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with only 1 sample being 9G4+RhF. Figure 4 similarly shows
results for patients within the ERA group. IgG-CCP2 positivity
was usually accompanied in the same sample by IgM-CCP2, IgA-
CCP2 and 9G4+CCP2. The presence and level of the RhF
response and 9G4+RhF expression did not correlate with presence
or levels of anti-CCP2 antibodies in the same patient. In the Est-
RA cohort (Figure 5), samples with the highest levels of IgG-CCP2
also contained IgM- and IgA-CCP2 and most were also positive
for IgM-RhF. The pattern of 9G4+CCP2 positivity corresponded
most closely with that of samples containing IgM- and IgA-CCP2
as well as IgG-CCP2.
Is 9G4 expression on IgM or IgG-anti-CCP2 antibodies?
Protein G columns were used to separate sera from 4 patients
with established RA (Figure S1). Following separation, results
suggested most 9G4 activity associated with the eluted fraction.
However, the eluted fractions contained both IgM- and IgG-
CCP2 activity, probably due to interference by Rheumatoid
factors. In the flow-through fractions only 1 serum was positive for
9G4-CCP2 binding. This fraction also had CCP2 binding activity
in both IgM- and -IgG-CCP2 assays, which may also be due to the
presence of high levels of Rheumatoid factors blocking Fcc
binding to Protein G. Results were therefore equivocal but
suggested that at least a proportion of 9G4+CCP2 were within the
IgG fraction.
Discussion
The ability to bind the rat monoclonal anti-idiotope antibody,
9G4, was used as a surrogate measure of the utilisation of the
VH4-34 heavy chain by the 2 main autoantibody specificities
present in sera from patients with RA. Our results showed that in
Figure 1. 9G4 expresssion on antibodies to CCP2 and on RhF in
early and established RA. 9G4 expression on CCP2 (A) and RhF (B) in
sera from healthy controls (HC), patients with very early RA (VERA), very
early non-RA (VENRA), early RA (ERA), early non-RA (ENRA) and a cohort
of seropositive established RA (Est-RA). Comparisons were with Mann
Whitney U test at 5% level.
doi:10.1371/journal.pone.0107513.g001
Figure 2. Percentages of samples positive for IgG-, IgA- and
IgM- anti-CCP2 antibodies and RhF and for 9G4 expression.
Isotypes of anti-CCP2 antibodies and 9G4 expression on CCP2 binding
antibodies are shown in (A) and isotypes of RhF and 9G4 expression of
antibodies binding to rabbit-IgG are shown in (B).
doi:10.1371/journal.pone.0107513.g002
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patients with early RA and with established disease, there was a
remarkably consistent recognition of anti-CCP2 antibodies by the
9G4 reagent. Positivity for binding of 9G4 to RhF was also found
but less frequently. Further, levels of binding to each autoantibody
specificity did not correlate in individual patients. This report is
the first, to our knowledge, to describe the apparent usage of the
inherently autoreactive VH4-34 gene by anti-CCP2 antibodies in
patients with RA from the very earliest signs of disease.
Unaffected relatives of RA patients, as well those with an
undifferentiated arthritis, can test positive for ACPA (and RhF)
[33]. In the present study, we found that although IgM-CCP2 and
IgM-RhF could both be present in sera from VENRA and ENRA
patients, where synovitis failed to develop into RA, 9G4 expression
on anti-CCP2 antibodies was present in only 2 samples, and at
very low levels. Both samples were from VENRA patients, and
contained only IgM-class anti-CCP2.
In normal individuals, VH4-34 usage by total serum immuno-
globulins (both IgM and IgG) is disproportionately low (,0.7% of
serum IgM; no IgG) given that 5–10% of peripheral B-cells
express the 9G4 idiotope [20,34]. Consistent with a lack of class-
Figure 3. 9G4 expression and relative levels of autoantibodies in individual patients in the ERA cohort. Results for all autoantibody
isotypes and for 9G4 expression were ranked in order of the relative levels of IgG-CCP2 in order to follow results for individual patients (as numbered
on x-axis). Horizontal dotted lines show upper limit of normal ranges determined for each parameter as described in the text.
doi:10.1371/journal.pone.0107513.g003
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Figure 4. 9G4 expression and relative levels of autoantibodies in individual patients in the ERA cohort. Results for all autoantibody
isotypes and for 9G4 expression were ranked in order of the relative levels of IgG-CCP2 in order to follow results for individual patients (as numbered
on x-axis). Horizontal dotted lines show upper limit of normal ranges determined for each parameter as described in the text.
doi:10.1371/journal.pone.0107513.g004
9G4 Expression on Autoantibodies in RA Patients
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e107513
switched 9G4+Ig, 9G4+ B-cells are absent from tonsillar germinal
centres in healthy individuals [35]. Following infections, such as
with EBV, antibodies utilising VH4-34 show a transient increase,
largely within the IgM pool. Expression of CD27 (expressed by
most but not all memory-B-cells [36]) can only be detected on a
small (,10%) sub-population of 9G4+ B-cells, but somewhat
unusually such cells can co-express the naı¨ve B cell marker, CD5
[37]. Taken together, these observations are consistent with the
VH4-34 gene being utilised by naı¨ve or pre-switch B-cells, which
display a limited ability to undergo class switch [15]. The presence
of such a high proportion of VH4-34-derived B-cells in the naı¨ve
compartment further suggest that this particular germ line
sequence is preferentially selected for exit from the bone marrow
into the periphery, regardless of CDR3 specificity.
In the context of autoimmunity, most notably SLE, class-
switched (IgG) 9G4+ anti-dsDNA antibodies are present in serum
and in involved renal tissue [25,34]. 9G4+ B-cells were also
abundant in germinal centre (GC) reactions in tonsils from SLE
patients but tonsils from RA patients resembled those of normal
individuals with 9G4+ B-cells thus being excluded [35]. In another
Figure 5. 9G4 expression and relative levels of autoantibodies in individual patients in the Est-RA cohort. Results for all autoantibody
isotypes and for 9G4 expression were ranked in order of the relative levels of IgG-CCP2 in order to follow results for individual patients (as numbered
on x-axis). Horizontal dotted lines show upper limit of normal ranges determined for each parameter as described in the text.
doi:10.1371/journal.pone.0107513.g005
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study, VH4-34 derived B-cells from normal human tonsils did
show evidence of class switch [38], but the anatomical location of
such B cells within the tonsil was not given. Somatic hypermuta-
tion was also detected before class switch in some clonally related
transcripts, suggesting that VH4-34 (m+) B-cells were indeed
capable of undergoing both somatic mutation and class-switch,
most likely outside a GC reaction [35].
We found that in samples from patients with the shortest history
of polyarthritis (VERA), 9G4+CCP2 was most strongly associated
with IgG-CCP2, particularly when co-existing in samples
containing IgM-RhF. Although the relative contribution of
different Ig isotypes to total 9G4-CCP2 binding was dificult to
interpret due to probable interference with RhF, our results using
Protein G columns (Figure S1) and pepsin digestion (data not
shown) nevertheless suggested that both IgM- and IgG-CCP2
autoantibodies can express the 9G4+ idiotope, consistent with the
possibility that class-switch of 9G4+CCP2 antibodies could occur.
9G4 expression on RhF in the RA cohorts was indeed found to
be less common and somewhat lower than on CCP2-directed
antibodies. In addition, the levels of 9G4 expression on antibodies
to CCP2 and on RhF in individual samples (Figures 3–5) showed
that the 9G4 idiotope was not necessarily present on both
autoantibody specificities in the same sample and if present,
relative expression usually differed. Expansion of 9G4+CCP2
autoreactivity was therefore both greater than that of 9G4+RhF,
particularly in early RA patients, and therefore was not likely to be
the result of a polyclonal expansion of all ‘autoreactive’ VH4-34-
derived parent B-cells. In addition, we found that 9G4 expression
was absent from antibodies to tetanus toxoid and pneumococcal
capsular polysaccharides within serum samples positive for 9G4-
CCP2 (Figure S2). This argues against a prior general expansion of
VH4-34 encoded antibodies and further suggests that autoantigen
specificity may play a role in the selection of particular 9G4+ B cell
clones.
Intriguingly, the percentage of samples positive for IgM- and for
IgA-CCP2 between VERA and ERA cohorts followed, rather
than preceded positivity for IgG-class antibodies to CCP2
(Figure 2A; Figures 3 and 4). This supports the suggestion that
the elicitation of IgG-CCP2 antibodies to a citrullinated protein
may arise early in the underlying pathogenic process and also
suggest a sequence of events not shared with conventional
antibody responses to immunisation or infection [39]. In
established RA, the persistence of multiple isotypes of anti-CCP2
over time, most notably in the IgM fraction, also indicates that
there is a constant renewal of autoreactive (naı¨ve) B-cells
throughout the course of disease which then differentiate into
plasmablasts, or long-lived plasma cells [40]. The kinetics of
autoantibody production following B-cell depletion treatment with
the anti-CD20 reagent, rituximab, have shown that at least a
proportion of IgM-autoantibodies derive from early/naı¨ve B-cells
continuously exiting the bone marrow; a process interupted by this
form of therapy [41]. Support for this scenario comes from the
experiments of Samuels et al [42] who reported that VH regions
cloned and translated from early naı¨ve B-cells from RA patients
contained a high proportion of transcripts with reactivity for
citrullinated peptides. This would suggest that in RA, autoreactive
B cell specificities escape deletion, receptor editing or anergy early
in their development, ultimately giving rise to a population of B-
cells which can also survive entry into the mature B cell
compartment in the periphery.
The unique properties of B-cells expressing both the inherently
autoreactive 9G4 epitope, coupled with specificity and high
affinities for citrullinated residues through CDR3 may conceivably
therefore be a key factor in the selection and possibly expansion of
the immune response to citrullinated proteins in RA patients.
Although B cell development in the bone marrow is largely
antigen-independent, signaling through a functional B cell
receptor complex (consisting of surface immunoglobulin, CD19
and co-receptors CD81, CD21), microenvironmental factors and
also interaction between pre-B-cells, influences selection during
differentiation towards entry into the peripheral pool. We have
previously suggested that the expansion of autoreactive B cell
clones in systemic autoimmune diseases relates to pro-survival
properties imbued by certain B-cell receptors [43]. VH4-34 usage,
combined with specificity for citrullinated residues, may therefore
increase the probability of positive BCR signalling in parent B cells
and contribute to the selection of auto-reactive B-cells either
before their exit from the bone marrow and/or in the periphery of
patients with RA.
Conclusion
In this cross-sectional study, seropositivity for autoantibodies
expressing the 9G4 idiotope apparently increased with disease
maturity in patients with RA. A higher proportion of patients with
the earliest symptoms of polyarthritis whose disease resolved into
Rheumatoid arthritis were also more likely to have 9G4+CCP2
than those with other diagnostic outcomes. The presence of 9G4+
antibodies of any isotype in the serum immunoglobulin pool is
unusual and is here clearly associated with autoimmunity. 9G4+
autoantibodies were able to be detected in the circulation from the
first weeks of resolution into RA and may thus represent a
surrogate measure of selection of autoreactive B-cells into the
periphery.
Supporting Information
Figure S1 9G4 binding to serum fractions separated by
Protein G columns. IgM- and IgG- anti-CCP2 and 9G4+
CCP2 reactivity was measured in sera from 4 patients with
established RA. Following separation on Protein G columns, flow
through and eluted fractions were tested for IgM-, IgG- and 9G4-
CCP2 activity.
(TIFF)
Figure S2 9G4 binding to antibodies to microbial
antigens. Antibodies to pneumococcal capsular polysaccharides
(PCP – consisting of a combination of 23 serotypes of
Streptococcus pneumoniae serotypes) and to tetanus toxoid (TT)
were measured by ELISA using commercial kits. 9G4 expression
on bound anti-microbial antibodies were then determined using
methods described for autoantibodies.
(TIFF)
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